Published in J Clin Oncol on April 13, 2017
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet (2010) 11.00
Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med (2007) 9.04
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. N Engl J Med (2016) 8.53
Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med (2013) 7.72
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med (2012) 7.47
Aspirin use and survival after diagnosis of colorectal cancer. JAMA (2009) 6.93
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut (2008) 6.26
Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10
Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer. JAMA Oncol (2016) 4.90
Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet (2012) 4.85
The consensus molecular subtypes of colorectal cancer. Nat Med (2015) 4.35
Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol (2015) 4.25
Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut (2010) 4.01
Review of inverse probability weighting for dealing with missing data. Stat Methods Med Res (2011) 3.56
The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov (2014) 3.32
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol (2010) 3.03
Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One (2008) 2.92
Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol (2013) 2.90
Cancer immunology--analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol (2011) 2.90
Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res (2009) 2.62
The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med (2015) 2.48
Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst (2010) 2.35
Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data. Stat Med (2005) 2.16
Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol (2000) 2.11
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell (2015) 2.10
Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci (2013) 2.00
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. Immunity (2016) 1.96
Review Article: The Role of Molecular Pathological Epidemiology in the Study of Neoplastic and Non-neoplastic Diseases in the Era of Precision Medicine. Epidemiology (2016) 1.89
Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology (2014) 1.84
Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis. Gut (2014) 1.71
PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Mod Pathol (2016) 1.40
Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. Clin Cancer Res (2009) 1.39
Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res (2003) 1.33
The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discov (2015) 1.24
Molecular pathological epidemiology gives clues to paradoxical findings. Eur J Epidemiol (2015) 1.16
Immune cells: plastic players along colorectal cancer progression. J Cell Mol Med (2013) 1.07
Colorectal cancer. Nat Rev Dis Prim (2015) 1.07
Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity. Breast Cancer Res (2013) 1.04
Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation. Cancer J (2014) 0.99
The invisible arm of immunity in common cancer chemoprevention agents. Cancer Prev Res (Phila) (2013) 0.92
Obesity and colorectal cancer: molecular features of adipose tissue. J Transl Med (2016) 0.90
Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology (2015) 0.88
Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity. Cell Death Dis (2014) 0.87
Tumor-Infiltrating Lymphocytes, Crohn's-Like Lymphoid Reaction, and Survival From Colorectal Cancer. J Natl Cancer Inst (2016) 0.85
Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut (2016) 0.83
Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas. Mod Pathol (2016) 0.80
The significantly enhanced frequency of functional CD4+CD25+Foxp3+ T regulatory cells in therapeutic dose aspirin-treated mice. Transpl Immunol (2009) 0.80
Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy. JAMA Oncol (2016) 0.78
Mismatch Repair and Colon Cancer: Mechanisms and Therapies Explored. Trends Mol Med (2016) 0.78
Immunotherapy: Evading immune escape: synergy of COX and immune-checkpoint inhibitors. Nat Rev Clin Oncol (2015) 0.77
The Role of Prostaglandin E2 in Tumor-Associated Immunosuppression. Trends Mol Med (2015) 0.76
Cytotoxic T-cells and granzyme B associated with improved colorectal cancer survival in a prospective cohort of older women. Cancer Epidemiol Biomarkers Prev (2016) 0.75